American Financial Advisors LLC Sells 24,000 Shares of Amarin Co. plc (NASDAQ:AMRN)

American Financial Advisors LLC decreased its position in shares of Amarin Co. plc (NASDAQ:AMRN) by 20.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 92,382 shares of the biopharmaceutical company’s stock after selling 24,000 shares during the period. American Financial Advisors LLC’s holdings in Amarin were worth $45,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its position in shares of Amarin by 8.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,301,468 shares of the biopharmaceutical company’s stock valued at $816,000 after purchasing an additional 104,939 shares during the period. LCM Capital Management Inc boosted its holdings in Amarin by 3.1% in the 4th quarter. LCM Capital Management Inc now owns 838,259 shares of the biopharmaceutical company’s stock worth $407,000 after buying an additional 25,100 shares during the period. Kornitzer Capital Management Inc. KS increased its stake in Amarin by 80.7% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 95,600 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 42,700 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Amarin by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 76,959 shares of the biopharmaceutical company’s stock valued at $48,000 after acquiring an additional 29,992 shares during the period. Finally, Arkfeld Wealth Strategies L.L.C. lifted its position in shares of Amarin by 52.6% in the fourth quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 20,000 shares in the last quarter. Hedge funds and other institutional investors own 22.25% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com upgraded Amarin from a “sell” rating to a “hold” rating in a research report on Tuesday, February 11th.

Amarin Price Performance

Amarin stock opened at $0.61 on Friday. The firm’s 50 day moving average price is $0.53 and its 200-day moving average price is $0.57. Amarin Co. plc has a 1 year low of $0.43 and a 1 year high of $1.36. The stock has a market cap of $251.49 million, a P/E ratio of -6.80 and a beta of 1.83.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.